SPONSOR
TG Therapeutics, Inc.
Total Trials
4
Recruiting
4
Phases
Phase 3, Phase 1
Conditions studied: Relapsing Multiple SclerosisMultiple SclerosisB-cell Mediated Autoimmune Disorders
TG Therapeutics, Inc. is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including Relapsing Multiple Sclerosis, Multiple Sclerosis, B-cell Mediated Autoimmune Disorders.
The trial portfolio spans Phase 3, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — TG Therapeutics, Inc.
How many clinical trials has TG Therapeutics, Inc. sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by TG Therapeutics, Inc., of which 4 are actively recruiting participants. These trials cover conditions including Relapsing Multiple Sclerosis, Multiple Sclerosis, B-cell Mediated Autoimmune Disorders. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does TG Therapeutics, Inc. research focus on?
TG Therapeutics, Inc. clinical trials span Relapsing Multiple Sclerosis, Multiple Sclerosis, B-cell Mediated Autoimmune Disorders. The research pipeline includes Phase 3, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a TG Therapeutics, Inc. clinical trial?
To participate in a TG Therapeutics, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all TG Therapeutics, Inc. trials with current recruitment status updated daily.
Clinical Trials by TG Therapeutics, Inc.
NCT06143514
Recruiting
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
Relapsing Multiple Sclerosis
NCT05877963 Phase 3
Recruiting
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
NCT06433752
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
NCT06680037 Phase 1
Recruiting
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
B-cell Mediated Autoimmune Disorders
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology